
## World Health Organization (WHO) report on my kesistance

Together We Can Take on Typhoid

A 2022 report<sup>1</sup> from WHO highlights the importance of the vaccine development pipeline through a lens of using vaccines to combat drug resistance. Based on published data, typhoid conjugate vaccines (TCVs) are powerful tools to limit the spread of drug-resistant typhoid.



- Drug-resistant infections
- Impact of vaccines to prevent the emergence of drug-resistance

A modeling analysis shows that TCV is likely cost-effective in countries with high typhoid incidence, high cost of typhoid treatment, and/or high death rates from typhoid

expensive and less available antibiotics at a higher price

to the patient and health care system

Recommendations

Increase vaccine coverage to maximize impact on drugresistant pathogens Increase vaccine coverage in countries that have already introduced TCV

Prioritize country decision-making for TCV introduction in typhoid endemic countries and countries with high burden of drug-resistant typhoid

1. Bacterial vaccines in clinical and preclinical development: An overview and analysis. Geneva: World Health Organization; 2022. Available at: https://www.who.int/publications/i/item/9789240052451.

## www.takeontyphoid.com

## September 2022